Status:
COMPLETED
Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.
Eligibility Criteria
Inclusion
- Generally healthy men and women with persistent asthma, 18 to 70 years of age, with body weight between 50 kg and 115 kg.
- History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with or without long-acting beta-agonists (LABA), for at least 2 months prior to the screening visit and must remain constant during the study.
- FEV1 ≥ 55% to ≤ 80% predicted and demonstrated improvement in FEV1 (L) with inhaled albuterol (salbutamol) (reversibility) of ≥ 12%.
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT00425061
Start Date
February 1 2007
End Date
August 1 2008
Last Update
January 14 2015
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Allergy and Asthma Center
Birmingham, Alabama, United States, 35209
2
Alabama Allergy & Asthma Clinic
Montgomery, Alabama, United States, 36106
3
Little Rock Allergy & Asthma
Little Rock, Arkansas, United States, 72205
4
Pacific Coast Allergy
Crescent City, California, United States, 95531